Skip to content

Is a Carnitine Based Food Supplement (PorimoreTM) for Infertile Men Superior to Folate and Zinc With Regard to Pregnancy Rates in Intrauterine Insemination Cycles?

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01075334
Enrollment
100
Registered
2010-02-25
Start date
2010-02-28
Completion date
2012-12-31
Last updated
2010-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Infertility

Keywords

sperm, male infertility, Carnitine, food supplementation, insemination

Brief summary

Many cases of male infertility are poorly understood and regarded as unexplained. Therefore, a etiological treatment for this condition can not be offered in most cases. A beneficial effect on sperm motility was found in trails using antioxidants such as carnitine, zinc and folic acid. However, most studies lacked a sufficient power to detect a significant effect on pregnancy rates. In this study, infertile men with abnormal sperm quality parameters will be randomized to receive either carnitine-based food supplement (Porimore) or folate and Zinc Tablets.

Interventions

DIETARY_SUPPLEMENTPorimore - A Carnitine based food supplement

A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.

DIETARY_SUPPLEMENTZinc and Folate Supplementation

500 Mcg Folic acid, 30-60 mg Zinc tablets/ day

Sponsors

Shaare Zedek Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* infertility * at least one abnormal sperm quality parameter * female age \< 35 * normal ovarian reserve

Exclusion criteria

* known allergy to one of the food additives planned for treatment

Design outcomes

Primary

MeasureTime frameDescription
Pregnancy Rate3 Insemination cyclesproportion of women becoming pregnancy following treatment with intrauterine insemination

Secondary

MeasureTime frame
Sperm quality parameters3 months

Countries

Israel

Contacts

Primary ContactAvi Tsafrir, MD
avits@szmc.org.il972-6555111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026